Skip to main content
. 2019 Nov 26;20(23):5942. doi: 10.3390/ijms20235942

Figure 5.

Figure 5

Schematic overview of the merits and challenges of CSPG4 for the CAR-T-cell therapy of triple-negative breast cancer.